(Q41817750)

12 October 2017

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil (English)

1 reference

12 October 2017

1 reference

2

Keith Wilner

1 reference

12 October 2017

Gary J Muirhead

1

1 reference

12 October 2017

Wayne Colburn

series ordinal

3

1 reference

12 October 2017

Gertrude Haug-Pihale

series ordinal

4

1 reference

12 October 2017

Bernhard Rouviex

series ordinal

5

1 reference

12 October 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

British Journal of Clinical Pharmacology

12 October 2017

1 reference

12 October 2017

53 Suppl 1

1 reference

12 October 2017

21S-30S

1 reference

Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Age-dependent changes of the kidneys: pharmacological implications

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1874252

Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs

6 June 2018

1 reference

12 December 2020

Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood

1 reference

12 December 2020

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence

1 reference

12 December 2020

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

12 December 2020

Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro

1 reference

12 December 2020

Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography

1 reference

12 December 2020

The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

1 reference

12 December 2020

Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells

1 reference

12 December 2020

Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man

1 reference

12 December 2020

10.1046/J.0306-5251.2001.00029.X

Identifiers

DOI

1 reference

12 October 2017

1 reference

12 October 2017

PubMed publication ID

11879256

1 reference